Trials / Recruiting
RecruitingNCT06984081
CAPA In-vitro Oocyte Maturation
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 100 (estimated)
- Sponsor
- Chinese University of Hong Kong · Academic / Other
- Sex
- Female
- Age
- 0 Months – 50 Years
- Healthy volunteers
- Accepted
Summary
In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | CAPA IVM | In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation. |
Timeline
- Start date
- 2025-11-10
- Primary completion
- 2030-05-31
- Completion
- 2032-05-31
- First posted
- 2025-05-22
- Last updated
- 2025-12-08
Locations
1 site across 1 country: Hong Kong
Source: ClinicalTrials.gov record NCT06984081. Inclusion in this directory is not an endorsement.